Research on prostate cancer has demonstrated that the depletion of CDC20 can enhance CD8 T lymphocyte infiltration in a GSDME-dependent manner, thereby amplifying antitumor immunity (77). This evidence concerns the gene CD8A and prostate carcinoma.